Syros rises 13% as tamibarotene gets FDA orphan drug status for myelodysplastic syndrome
03 February 2022 - 8:09AM
Seeking Alpha
To read the full story on Seeking Alpha, click
here.
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2024 to May 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From May 2023 to May 2024